Somerset Patent-Cliff Exposure & CMS Drug Spending Portfolio

Somerset (US): 1 reconciled FDA prescription therapies, $17.2M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$17.2M
2024 Medicare Part D Spend$12.5M
2024 Medicaid Spend$4.6M
California HCAI SB 17 Filings9 WAC filings (max 18.0% 2-yr change)